Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ventrus BioSciences to Announce 3Q 2011 Financial Results, Clinical Update and Omnibus Market Research Results: Conference Call and Webcast
NEW YORK , Nov. 9, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it will report on its clinical trial progress, the initial topline results of a market research study commissioned by it and conducted by Princeton Biometrics on the U.S.
View HTML
Toggle Summary Ventrus Announces the Launch of the First Pivotal Trial of VEN 309 for the Treatment of Hemorrhoids
NEW YORK , Aug. 16, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that enrollment has opened at 65 of the 70 sites that will participate in the first pivotal Phase III trial of VEN 309 for the treatment of symptomatic hemorrhoids, and patients have now entered the
View HTML
Toggle Summary Ventrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering
NEW YORK , July 19, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced that it closed today its previously announced underwritten registered offering of 5,175,000
View HTML
Toggle Summary Ventrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock
NEW YORK , July 14, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its underwritten registered offering of 4,500,000 shares of its common stock at a price
View HTML
Toggle Summary Ventrus Receives SPA Response From FDA and Will Update and File the First Pivotal Trial Protocol to its IND
NEW YORK , June 22, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to its last Special Protocol Assessment (SPA) submission for iferanserin (VEN 309) for the treatment of hemorrhoids,
View HTML
Toggle Summary Ventrus Receives Notice of Allowance for U.S. Patent for VEN 307
U.S. Patent Office Allows Claims for 2% Diltiazem Cream for Treatment of Anal Fissures
View HTML
Toggle Summary Ventrus Adds Third Treatment Arm of Shorter Treatment Duration to Its Phase III Study of Iferanserin in Hemorrhoids
NEW YORK , May 2, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has added a third treatment arm to its first pivotal Phase III study of Iferanserin (VEN 309), the first prescription product candidate for the treatment of hemorrhoids.
View HTML
Toggle Summary Ventrus Announces Improved, FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study
Company to Host Conference Call on Monday, March 21 at 8:30 AM ET
View HTML
Toggle Summary Background Information to Improved FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study
Background Information to Improved FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study
View HTML
Toggle Summary Ventrus Hires inVentiv Clinical Solutions and Almac Group for Its Phase III Pivotal Trial in the Treatment of Hemorrhoids With Iferanserin Ointment
NEW YORK , March 3, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has selected inVentiv Clinical Solutions to manage its Phase III pivotal trial with Iferanserin
View HTML